Efficacy and Safety of Everolimus in Patients With Metastatic RCC After Failure of First-Line Sunitinib or Pazopanib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
A Phase 4 Study of Everolimus to Evaluate Efficacy and Safety in Patients With Metastatic Renal-Cell Carcinoma After Failure of First-Line Sunitinib or Pazopanib (SUNPAZ)
Urol. Int. 2019 Nov 14;[EPub Ahead of Print], M Schostak, P de Geeter, T Decker, A Resch, C Quiering, S SchmitzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.